FEV1 от 21% (16% до 33%) спрямо изходното ниво и са били лекувани с EXUBERA средно ве
These subjects experienced an average decrease in FEV1 of 21% (range 16%-33%) from baseline and were treated with EXUBERA for an average of 23 months.